Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems
Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems.
You may also be interested in...
Pink Sheet reporters and editors consider the implications of a Democratic Congress for the pharma industry, ongoing problems with slow coronavirus vaccination rates, and the high CDER novel approval count in 2020.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Pink Sheet reporters and editors discuss their take-aways from the recent advisory committee meeting on coronavirus vaccine development and approval, as well as the upcoming FDA hearing on Makena’s withdrawal.